Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era

Overview of attention for article published in Frontiers in oncology, October 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 4 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 18,700 followers.

RT @FrontOncology: New research: Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era: Background Diffuse large B-ce…

07 Oct 2023

Reply Repost Favourite

New research: Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era: Background Diffuse large B-cell lymphoma (DLBCL) is an aggressive and the most common type of non-Hodgkin lymphoma (NHL). The clinical use of rituximab… #oncology ht

06 Oct 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.